Core Insights - CorMedix Inc. reported a net revenue of $128.6 million for Q4 2025, with a full-year pro forma revenue of $401.3 million, reflecting significant growth compared to the previous year [1][4][8] - The company achieved a net income of $14.0 million in Q4 2025, with an adjusted EBITDA of $77.2 million, indicating strong operational performance [1][7][8] - CorMedix is focused on expanding patient access to its product DefenCath and has completed the acquisition of Melinta, which is expected to enhance its product portfolio [3][4] Financial Highlights - Q4 2025 net revenue included $91.2 million from DefenCath sales and $37.4 million from the Melinta portfolio, marking an increase from $31.2 million in Q4 2024 [4][5] - Total operating expenses for Q4 2025 were $48.2 million, a significant increase from $17.1 million in Q4 2024, primarily due to the Melinta acquisition and associated costs [5][9] - For the full year 2025, CorMedix reported total revenue of $311.7 million, with net sales of DefenCath at $258.8 million and net revenue from Melinta at $52.9 million [8][9] Operational Developments - The company has initiated a share repurchase program authorizing up to $75 million of its common stock [5] - CorMedix anticipates clinical data from the Phase 3 ReSPECT study of REZZAYO in Q2 2026, which is crucial for its growth strategy [5][14] - The ongoing Phase 3 study of taurolidine/heparin catheter lock solution in TPN patients is expected to complete enrollment in the first half of 2027 [5][14] Cash Position - As of December 31, 2025, CorMedix had cash and short-term investments totaling $148.5 million, excluding restricted cash [10][22]

Core Viewpoint - CorMedix Therapeutics has announced a share repurchase program authorizing the repurchase of up to $75 million of its outstanding common stock, effective through December 31, 2027 [1] Financial Position - The company has a strong balance sheet with approximately $150 million in cash and cash equivalents as of December 31, 2025, and 79.3 million common shares outstanding [2] - The share repurchase program is seen as a disciplined way to return value to shareholders while maintaining financial flexibility for business investments [2] Share Repurchase Program Details - Repurchases may occur at management's discretion through various methods, including privately negotiated transactions, block trades, and open market purchases [3] - The program is subject to market conditions, liquidity, cash flow considerations, and applicable securities laws [3] - There is no obligation for CorMedix to repurchase any specific amount of shares, and the program may be suspended or discontinued at any time [3] Company Overview - CorMedix is focused on developing and commercializing therapeutic products for life-threatening conditions, including the commercialization of DefenCath for preventing catheter-related bloodstream infections [4] - Following the acquisition of Melinta Therapeutics LLC in August 2025, CorMedix is also commercializing a portfolio of anti-infective products [4] Clinical Development - CorMedix has ongoing clinical studies for DefenCath in Total Parenteral Nutrition and Pediatric Hemodialysis populations, with plans to develop it as a catheter lock solution for other patient populations [5] - REZZAYO is approved for treating candidemia and invasive candidiasis in adults, with a Phase III study ongoing for prophylaxis of invasive fungal disease in adult patients undergoing allogeneic bone marrow transplantation, with topline results expected in Q2 2026 [5]

Core Insights - CorMedix Inc. reported Q3 2025 net revenue of $104.3 million and pro forma net revenue of $130.8 million, primarily driven by increased utilization of DefenCath by outpatient dialysis customers [4] - The company raised its full-year 2025 pro forma net revenue guidance to a range of $390 to $410 million, with fourth quarter guidance set between $115 to $135 million [4] - CorMedix achieved a net income of $108.6 million for Q3 2025, significantly improving from a net loss of $2.8 million in Q3 2024, aided by a one-time tax benefit of $59.7 million [3][4] Financial Performance - Q3 2025 net revenue was $104.3 million, with DefenCath sales contributing $88.8 million [4] - Adjusted EBITDA for Q3 2025 was reported at $71.9 million, with basic and diluted EPS at $1.42 and $1.26, respectively [4][3] - Total operating expenses for Q3 2025 were $41.7 million, a 197% increase from $14.1 million in Q3 2024, driven by non-recurring costs related to the Melinta acquisition [5] Business Developments - CorMedix completed the acquisition of Melinta Therapeutics on August 29, 2025, with integration efforts proceeding faster than expected, estimating a synergy capture of approximately $30 million [4] - The company announced a rebranding to CorMedix Therapeutics, with all employees operating under the new name [4] - CorMedix completed enrollment in the Phase III ReSPECT study for Rezzayo in October 2025, expecting top-line data in Q2 2026 [4] Cash Position - As of September 30, 2025, CorMedix reported cash and short-term investments of $55.7 million, projecting year-end cash of approximately $100 million [6][4]